Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 16,311 shares, a growth of 345.3% from the July 15th total of 3,663 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 9,444 shares, the days-to-cover ratio is currently 1.7 days.

Elekta Stock Performance

OTCMKTS:EKTAY opened at $5.46 on Wednesday. The company has a market capitalization of $2.01 billion, a P/E ratio of -34.12 and a beta of 1.01. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. Elekta has a 12 month low of $4.35 and a 12 month high of $6.93. The firm has a fifty day simple moving average of $5.15 and a 200-day simple moving average of $5.77.

Elekta (OTCMKTS:EKTAY) last released its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. The firm had revenue of $521.00 million for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. On average, equities research analysts anticipate that Elekta will post 0.43 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.